The TAXUS Express2 is a stainless steel stent that uses Paclitaxel and Translute polymer to control the drug release. Clinical trials consistently show low TLR and MACE rates compared to the bare metal control arm among a variety of patients and lesions. It is available in over-the-wire and monorail systems in a full product matrix, from 2.50 to 3.5 mm diameters and 8 to 32 mm lengths.
If you enjoy this content, please share it with a colleague
Stent Trials Show Low TLR, MACE Rates
Related Content
July 2, 2024 — Biotronik announced the availability of an expanded Maximum Allowed Diameters (MAD) range for the Orsiro ...
October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...
October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...
July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...
July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...
May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...
December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...
June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...